Treatment-related adverse effects of the sintilimab-anlotinib combination regimen included hand-foot syndrome and hyponatremia.
Susan Moench, PhD, PA-COncology Writer
Susan Moench has been working as a medical writer since 2003. Prior to joining the staff of Cancer Therapy Advisor and Oncology Nurse Advisor as an oncology writer, she spent approximately 4 years as a medical writer at the Rutgers Cancer Institute of New Jersey, where she collaborated with oncologists on clinical trial protocols and publications related to precision oncology. Previous positions included approximately 5 years as an oncology scientist/senior medical writer at the National Comprehensive Cancer Network (NCCN), where she contributed to the development and update of clinical practice guidelines covering the diagnosis and treatment of a broad range of malignancies as well as supportive care issues in cancer. Susan received her PhD in Biochemistry from Colorado State University; she also holds an MS in Physician Assistant studies from DeSales University and is a certified physician assistant.